Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nanometer antibody for resisting B cell growth stimulating factor and use thereof

A nano-antibody and growth-stimulating technology, which is applied in the direction of anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody, anti-animal/human immunoglobulin, etc. It can solve the problems that there are no nano-antibody reports yet , to achieve the effect of inhibiting the proliferation or survival of B cells

Active Publication Date: 2015-07-29
TIANJIN SHENGFA NABIOTECH
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] No nanobodies against BAFF have been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanometer antibody for resisting B cell growth stimulating factor and use thereof
  • Nanometer antibody for resisting B cell growth stimulating factor and use thereof
  • Nanometer antibody for resisting B cell growth stimulating factor and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Expression of BAFF extracellular segment protein

[0054] 1. Fishing for sBAFF gene: Take normal human venous blood, and extract peripheral blood mononuclear cells (PBMC) according to conventional methods. The extraction of RNA was carried out according to the instruction of Invitorgen Company. 3ug RNA was reverse-transcribed to prepare a cDNA template, which was used as a template to amplify the BAFF gene.

[0055] The primer sequences are:

[0056] 5'CGGGAATTCCTGGTGCCACGCGGTGCCGTCAGGGTCCAGAAG3' (SEQ ID No. 3)

[0057] 5'CCCAAGCTTTCACAGCAGTTTCAATGC3' (SEQ ID No. 4)

[0058] PCR reaction conditions:

[0059]

[0060] 2. Construction of expression vectors: PCR amplification products were separated and recovered by agarose gel electrophoresis, digested with EcoRI (BioLab Company), HindIII (BioLab Company), and treated with the same enzyme as vector pET-30a (Sigma) by 3 :1 end ratio for cohesive end ligation. The ligation product was transformed into co...

Embodiment 2

[0065] Embodiment 2: Construction of anti-BAFF specific nanobody library

[0066] 1. Immune the alpaca, and analyze the production of nanobodies by enzyme immunoassay.

[0067] A total of 1.5 mg of antigen was injected subcutaneously at multiple points on the neck and back of the alpaca, and Freund's adjuvant was added, and the immunization was divided into 4 times. The absorption of the injected mass was followed up to confirm the correct immunization. Serum antibody titers were determined one month after the first immunization ( figure 2 ); after immunization, the interval between each immunization was halved, and the titer was determined. Use Protein G column and affinity chromatography to separate the serum one week after the fourth immunization, and detect the heavy chain antibody production and antibody titer by ELISA. After the fourth immunization, the titer of alpaca immune serum can reach 1: 10000. ( image 3 ).

[0068] 2. Isolation of Alpaca Peripheral Blood L...

Embodiment 3

[0098] Embodiment 3: the acquisition of anti-BAFF nanobody

[0099] 1. Screening of anti-BAFF-specific nanobodies

[0100] Using biotinylated BAFF antigen, the anti-BAFF nanobody was screened from the phage library by streptavidin magnetic beads method. The biotin-labeled BAFF antigen was mixed with the phage antibody library in proportion, and reacted overnight at 4°C. Add the antigen-phage antibody complex into the EP tube containing streptavidin magnetic beads, and roll and rotate for 0.5h to fully combine the magnetic beads with the biotin-labeled antigen-phage antibody complex. After each washing with PBST (0.05% T20) and PBS for 10 times, the phages were eluted with TEA and allowed to stand at room temperature for 10 minutes. 1M Tris-HCl neutralized TEA, kept on ice. Infect the bacteriophage with semi-logarithmic phase growth TG1, take appropriate amount of bacterial solution and dilute it, spread it on AMP / LB plate, incubate at 32°C, measure the titer of the eluent, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a nanometer antibody for resisting a B cell growth stimulating factor and a use thereof and belongs to the field of biotechnology. The nanometer antibody for resisting a B cell growth stimulating factor has an amino acid sequence shown in the formula of SEQ ID NO. 1 in the sequence table. Through screening of multiple nanometer antibodies with high activity and a latent neutralising capacity, the nanometer antibody 52 for resisting BAFF is obtained. The nanometer antibody can specifically bond with a human BAFF antigen, adjust biological activity of the BAFF antigen and related ligands, and effectively inhibit bonding of the BAFF antigen and its acceptors and production of corresponding signal cascade effects. The nanometer antibody for resisting BAFF can block combination of BAFF and its three related receptors, can substantially inhibit B cell proliferation or viability and can be used for detection and / or treatment on a plurality of BAFF expression abnormity-related diseases.

Description

technical field [0001] The invention relates to a nanobody against B cell growth stimulating factor and its application, belonging to the field of biotechnology. Background technique [0002] Lymphoma is a malignant tumor that originates in lymph nodes or lymphoid tissue. It has massive proliferation of lymphocytes and (or) histiocytes. It accounts for the eighth place among common malignant tumors in my country, and the trend of getting younger is obvious. In recent years, the incidence rate has increased from 2 to 4 / 100,000 rose to 6.91 / 100,000, and increased at a rate of 5% per year, with about 50,000 new patients and more than 20,000 deaths each year. It is generally believed that Hodgkin's lymphoma is mainly derived from B cells, and most non-Hodgkin's lymphomas are also derived from B cells. Therefore, treating lymphoma by eliminating B cells has become a new treatment plan. [0003] Clinical studies have found that malignant B cells such as lymphoma can synthesize an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13C12N15/70C12N1/21C12P21/02A61K39/395A61P35/00A61P35/02A61P37/02A61P29/00G01N33/68
Inventor 孙剑李胜华张伟京武文任光达
Owner TIANJIN SHENGFA NABIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com